Related Experiment Videos
Competitive cAMP antagonists for cAMP-receptor proteins
The Journal of Biological Chemistry
|August 25, 1984
Summary
Modified cyclic adenosine monophosphate (cAMP) molecules, cAMPS and cAMPN(CH3)2, show varied agonistic and antagonistic activities. The (SP) diastereomers act as agonists, while (RP) diastereomers exhibit antagonist properties in cAMP-dependent pathways.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Cyclic adenosine monophosphate (cAMP) is a crucial second messenger regulating diverse cellular processes.
- Modifications to the cAMP structure can yield derivatives with altered biological activities.
- Chirality introduced at the phosphorus atom of cAMP derivatives leads to diastereoisomers with potentially distinct functions.
Purpose of the Study:
- To synthesize and characterize chiral cAMP derivatives, specifically cAMPS and cAMPN(CH3)2.
- To investigate the agonistic and antagonistic activities of these diastereomers in key cAMP-dependent cellular events.
- To elucidate the structure-activity relationships of these novel cAMP analogs.
Main Methods:
- Synthesis of sulfur- and dimethylamino-substituted cAMP derivatives (cAMPS and cAMPN(CH3)2).
- Preparation of diastereoisomers: (SP) and (RP) forms for each derivative.
- Assay of agonistic/antagonistic activities in four cAMP-dependent systems: Dictyostelium discoideum cell surface cAMP receptor activation, and phosphorylation by mammalian protein kinases type I and II, and Dictyostelium protein kinase D.
Main Results:
- (SP)-cAMPS and (SP)-cAMPN(CH3)2 function as potent agonists across all tested cAMP-dependent reactions, with half-maximal activation in the micromolar range.
- (RP)-cAMPS acts as a full antagonist for the cell surface receptor and protein kinases I and II, and a partial agonist for protein kinase D.
- (RP)-cAMPN(CH3)2 is a full antagonist for the cell surface receptor and protein kinase II, a partial agonist for protein kinase I, and inactive against protein kinase D, showing lower antagonist potency than (RP)-cAMPS.
- Competitive antagonism of cAMP by (RP)-cAMPS was confirmed at micromolar concentrations.
Conclusions:
- Chirality at the phosphorus atom significantly dictates the biological activity of cAMP derivatives.
- (SP) diastereomers generally retain or enhance agonistic properties, while (RP) diastereomers exhibit antagonist or partial agonist activities.
- These chiral cAMP analogs serve as valuable tools for dissecting cAMP-mediated signaling pathways and hold potential for therapeutic applications.